ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Takeda to sell dengue vaccine abroad, starting with Indonesia

Japan's first global vaccine can be used for children younger than existing shots

Takeda is investing 130 million euros ($132 million) to build a plant in Germany that can make 50 million doses of its dengue vaccine a year. (Photo courtesy of the company)

TOKYO -- A dengue fever vaccine developed by Japan's Takeda Pharmaceutical has completed clinical trials and is expected to be approved in Indonesia soon, Nikkei has learned.

This will be the first global launch of a vaccine by a Japanese company. Takeda has already applied for approval of its dengue vaccine in Asia and South America, as well as Europe. The company aims to market the vaccine in about 30 countries and generate annual sales of $1.6 billion.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more